Patent · US Active

Anti-CCL17 antibodies

US11414484B2 · kind B2 · utility

0Cited by
25References
12Claims
0Family size

Assignee

Inventors

Key dates

Filing dateOct 1, 2020
Grant dateAug 16, 2022
Priority date
Expiry dateFeb 3, 2041

Classification

  • Technology area (CPC Y)Emerging Cross-Sectional Technologies
  • CPC primaryY02A50/30
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present invention relates to antibodies specifically binding CCL17, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.